While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly stock dips after missing a priority voucher and price cut talks on rival obesity drugs. Read more here.

Eli Lilly's new U.S. facility will be just the first of four that it plans to build in the country. The company expects to ...

(Reuters) -Eli Lilly said on Thursday the U.S. Food and Drug Administration has approved its treatment for a form of advanced ...

Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...